Restatement of Previously Issued Financial Statements - Schedule of Restated Audited Consolidated Statement of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2025 |
Mar. 31, 2025 |
Dec. 31, 2024 |
Mar. 31, 2025 |
Jun. 30, 2025 |
Sep. 30, 2025 |
Sep. 30, 2024 |
||||||||
| Restated Audited Consolidated Statement of Operations [Line Items] | ||||||||||||||
| Cost of revenue, net | $ 746 | $ 802 | $ 443 | $ 1,245 | $ 1,991 | $ 3,235 | $ 1,537 | |||||||
| Gross profit | 431 | [1] | 365 | [1] | 814 | [1] | 1,179 | [1] | 1,610 | [1] | 1,810 | 2,703 | ||
| Research and development | 3,302 | 2,635 | ||||||||||||
| Sales and marketing | 741 | 1,315 | ||||||||||||
| General and administrative | 1,409 | 4,757 | 4,014 | 8,771 | 10,180 | 14,967 | 6,533 | |||||||
| Total operating expenses | 2,230 | [1] | 5,447 | [1] | 4,743 | [1] | 10,190 | [1] | 12,420 | [1] | 19,010 | 10,483 | ||
| Income (loss) from operations | (1,800) | [1] | (5,082) | [1] | (3,929) | [1] | (9,011) | [1] | (10,810) | [1] | (17,200) | (7,780) | ||
| Other income (loss) | (286) | 4,128 | (25,965) | (21,837) | (22,123) | (34,172) | 7,587 | |||||||
| Total other expenses | 118 | [1] | 4,510 | [1] | (25,636) | [1] | (21,126) | [1] | (21,008) | [1] | (32,078) | 6,838 | ||
| Loss before income tax expense | (1,681) | [1] | (572) | [1] | (29,565) | [1] | (30,137) | [1] | (31,818) | [1] | (49,278) | (942) | ||
| Income tax benefit / (expense) | 9 | [1] | 96 | (426) | ||||||||||
| Consolidated net loss | (572) | [1] | (29,565) | [1] | (30,137) | [1] | (31,827) | [1] | (49,074) | (1,368) | ||||
| Net loss attributable to common stockholders | $ (1,650) | [1] | $ (555) | [1] | $ (29,544) | [1] | $ (30,099) | [1] | $ (31,749) | [1] | $ (49,073) | $ (1,368) | ||
| Basic net loss per share of common stock (in Dollars per share) | $ (0.01) | $ (0) | $ (0.31) | $ (0.29) | $ (0.29) | $ (0.4) | $ (0.02) | |||||||
| Diluted net loss per share of common stock (in Dollars per share) | $ (0.01) | $ (0) | $ (0.31) | $ (0.29) | $ (0.29) | $ (0.4) | $ (0.02) | |||||||
| As Previously Reported [Member] | ||||||||||||||
| Restated Audited Consolidated Statement of Operations [Line Items] | ||||||||||||||
| Cost of revenue, net | $ 301 | $ 454 | $ 123 | $ 577 | $ 878 | $ 1,756 | $ 1,520 | |||||||
| Gross profit | 876 | [1] | 713 | [1] | 1,134 | [1] | 1,847 | [1] | 2,723 | [1] | 3,289 | 2,720 | ||
| Research and development | 2,432 | 2,021 | ||||||||||||
| Sales and marketing | 1,262 | |||||||||||||
| General and administrative | 4,562 | 4,962 | 4,303 | 9,265 | 13,827 | 17,539 | 6,457 | |||||||
| Total operating expenses | 5,383 | [1] | 5,652 | [1] | 5,032 | [1] | 10,684 | [1] | 16,067 | [1] | 21,233 | 9,793 | ||
| Income (loss) from operations | (4,507) | [1] | (4,939) | [1] | (3,898) | [1] | (8,837) | [1] | (13,344) | [1] | (17,944) | (7,073) | ||
| Other income (loss) | ||||||||||||||
| Total other expenses | 404 | [1] | 382 | [1] | 329 | [1] | 711 | [1] | 1,115 | [1] | 2,094 | (749) | ||
| Loss before income tax expense | (4,103) | [1] | (4,557) | [1] | (3,569) | [1] | (8,126) | [1] | (12,229) | [1] | (15,850) | (7,822) | ||
| Income tax benefit / (expense) | [1] | (12) | (318) | |||||||||||
| Consolidated net loss | (4,557) | [1] | (3,569) | [1] | (8,126) | [1] | (12,238) | [1] | (15,862) | (8,140) | ||||
| Net loss attributable to common stockholders | $ (4,063) | [1] | $ (4,540) | [1] | $ (3,548) | [1] | $ (8,088) | [1] | $ (12,151) | [1] | $ (15,754) | $ (8,140) | ||
| Basic net loss per share of common stock (in Dollars per share) | $ (0.04) | $ (0.04) | $ (0.04) | $ (0.08) | $ (0.11) | $ (0.13) | $ (0.12) | |||||||
| Diluted net loss per share of common stock (in Dollars per share) | $ (0.04) | $ (0.04) | $ (0.04) | $ (0.08) | $ (0.11) | $ (0.13) | $ (0.12) | |||||||
| Restatement Adjustment [Member] | ||||||||||||||
| Restated Audited Consolidated Statement of Operations [Line Items] | ||||||||||||||
| Cost of revenue, net | $ 445 | $ 348 | $ 320 | $ 668 | $ 1,113 | $ 1,479 | $ 17 | |||||||
| Gross profit | (445) | [1] | (348) | [1] | (320) | [1] | (668) | [1] | (1,113) | [1] | (1,479) | (17) | ||
| Research and development | 870 | 614 | ||||||||||||
| Sales and marketing | (521) | |||||||||||||
| General and administrative | (3,153) | (205) | (289) | (494) | (3,647) | (2,572) | 76 | |||||||
| Total operating expenses | (3,153) | [1] | (205) | [1] | (289) | [1] | (494) | [1] | (3,647) | [1] | (2,223) | 690 | ||
| Income (loss) from operations | 2,707 | [1] | (143) | [1] | (31) | [1] | (174) | [1] | 2,534 | [1] | 744 | (707) | ||
| Other income (loss) | (286) | 4,128 | (25,965) | (21,837) | (22,123) | (34,172) | 7,587 | |||||||
| Total other expenses | (286) | [1] | 4,128 | [1] | (25,965) | [1] | (21,837) | [1] | (22,123) | [1] | (34,172) | 7,587 | ||
| Loss before income tax expense | 2,422 | [1] | 3,985 | [1] | (25,996) | [1] | (22,011) | [1] | (19,589) | [1] | (33,428) | 6,880 | ||
| Income tax benefit / (expense) | 9 | [1] | 108 | (108) | ||||||||||
| Consolidated net loss | 3,985 | [1] | (25,996) | [1] | (22,011) | [1] | (19,589) | [1] | (33,320) | 6,772 | ||||
| Net loss attributable to common stockholders | $ 2,413 | [1] | $ 3,985 | [1] | $ (25,996) | [1] | $ (22,011) | [1] | $ (19,598) | [1] | (33,320) | $ 6,772 | ||
| As Restated [Member] | ||||||||||||||
| Restated Audited Consolidated Statement of Operations [Line Items] | ||||||||||||||
| Consolidated net loss | (49,182) | |||||||||||||
| Net loss attributable to common stockholders | $ (49,074) | |||||||||||||
| ||||||||||||||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|